TITLE

Atherothrombotic events and clopidogrel therapy

AUTHOR(S)
McLachlan, Craig S.; Tay, Stacey K. H.; Almsherqi, Zakaria; Chia, Shu-Hui
PUB. DATE
January 2007
SOURCE
CMAJ: Canadian Medical Association Journal;1/30/2007, Vol. 176 Issue 3, p349
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
A letter to the editor is presented in response to the article "Increased risk of atherothrombotic events associated with cytochrome P4503A5 polymorphism in patients taking clopidogrel," by J. W. Suh, B. K. Koo, S. Y. Zhang and colleagues in volume 174, 2006 issue.
ACCESSION #
23761606

 

Related Articles

  • Cytochrome P-450 Polymorphisms and Response to Clopidogrel. Taubert, Dirk; Bouman, Heleen J.; van Werkum, Jochem W. // New England Journal of Medicine;5/21/2009, Vol. 360 Issue 21, p2249 

    The article presents a letter to the editor in response to the article "Cytochrome P-450 polymorphisms and response to clopidogrel" by J.L. Mega, S.L. Close, S.D. Wiviott, et al published in the January 22, 2009 issue.

  • Cytochrome P-450 Polymorphisms and Response to Clopidogrel. Miao, Jianting; Liu, Rui; Li, Zhuyi // New England Journal of Medicine;5/21/2009, Vol. 360 Issue 21, p2249 

    The article presents a letter to the editor in response to the article "Cytochrome P-450 polymorphisms and response to clopidogrel" by J.L. Mega, S.L. Close, S.D. Wiviott, et al published in the January 22, 2009 issue and addresses the article "Genetic determinants of response to clopidogrel and...

  • Cytochrome P-450 Polymorphisms and Response to Clopidogrel. Mega, Jessica L.; Wiviott, Stephen D.; Sabatine, Marc S. // New England Journal of Medicine;5/21/2009, Vol. 360 Issue 21, p2249 

    The article presents a letter to the editor from the author Mega and colleagues responding to Taubert and colleagues about their article "Cytochrome P-450 polymorphisms and response to clopidogrel" published in the January 22, 2009 issue.

  • Cytochrome P450 and gene activation – cholesterol elimination and regression of atherosclerosis: author reply to the commentary. Luoma, Pauli V. // European Journal of Clinical Pharmacology;Jan2009, Vol. 65 Issue 1, p105 

    A response by Pauli V. Luoma to a letter to the editor about his article "Cytochrome P450 and gene activation--from pharmacology to cholesterol elimination and regression of atherosclerosis" published in a previous issue is presented.

  • Response to ‘Overexpression of cytochrome P450 4F2 in mice increases 20-hydroxyeicosatetraenoic acid production and arterial blood pressure’. Xiaoliang Liu; Yanyan Zhao // Kidney International;Oct2009, Vol. 76 Issue 8, p913 

    A response by Xiaoliang Liu and colleagues to a letter to the editor about their study on the overexpression of cytochrome P450 4F2 in mice that increases arterial blood pressure and 20-hydroxy-eicosatetraenoic acid (HETE)production is presented.

  • Overexpression of cytochrome P450 4F2 in mice increases 20-hydroxyeicosatetraenoic acid production and arterial blood pressure. Fava, Cristiano; Montagnana, Martina; Melander, Olle // Kidney International;Oct2009, Vol. 76 Issue 8, p913 

    A letter to the editor is presented in response to the article "Overexpression of cytochrome P450 4F2 in mice increases 20-hydroxyeicosatetraenoic acid production and arterial blood pressure," by X. Liu and colleagues.

  • Illuminating Role of CYP1A1 in Skin Function. Rowe, Jo M; Welsh, Claire; Pena, Romi N; Wolf, C Roland; Brown, Ken; Whitelaw, C Bruce A // Journal of Investigative Dermatology;Jul2008, Vol. 128 Issue 7, p1866 

    A letter to the editor about the role of cytochrome P450 1A1 in skin function is presented.

  • Limited association of the 2988G>A single nucleotide polymorphism with CYP2D6*41 in black subjects. Gaedigk, Andrea; Ndjountché, Liliane; Leeder, J. Steven; Bradford, L. DiAnne // Clinical Pharmacology & Therapeutics;Mar2005, Vol. 77 Issue 3, p229 

    A letter to the editor is presented in response to the article "A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects," by S. Raimundo, C. Toscano, K. Klein, J. Fischer, E-U Griese, and M. Eichel-baum in the August 2004 issue.

  • Reply. Zanger, Ulrich M.; Schwab, Matthias; Toscano, Claudia; Eichelbaum, Michel; Sebastian Raimundo // Clinical Pharmacology & Therapeutics;Mar2005, Vol. 77 Issue 3, p230 

    A response by S. Raimundo, C. Toscano, K. Klein, J. Fischer, E-U Griese, and M. Eichel-baum to a letter to the editor about their article "A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects" in the August 2004 issue is presented.

  • Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam. Drabant, Sándor; Tóth, Mária; Bereczki, Andrea; Bajnógel, Judit; Tömlö, Judit; Klebovich, Imre // European Journal of Clinical Pharmacology;Jul2006, Vol. 62 Issue 7, p587 

    A letter to the editor is presented about a study conducted to evaluate the effect of tofisopam on cytochrome P450 3A4 enzyme activity, using alprazolam as a probe drug.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics